Opioid expenditures and utilization in the Medicaid system

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Public Health

Background:

• The U.S. Medicaid program is a significant payer for prescription drugs.
• Opioid medications are widely prescribed for pain management.
• Understanding trends in opioid utilization and cost is crucial for healthcare policy.

Purpose of the Study:

• To analyze trends in the utilization and expenditures of opioid medications within the U.S. Medicaid program.
• To compare opioid spending patterns across different states.
• To identify the contribution of specific opioid classes to overall cost increases.

Main Methods:

• Analysis of prescription data from the Centers for Medicare and Medicaid Services (CMS) Medicaid database.
• Examination of trends from 1998 to 2003 for the U.S. and seven selected states.
• Categorization of opioid medications, focusing on morphine derivatives.

Main Results:

• Total Medicaid opioid prescriptions nearly doubled between 1998 and 2003.
• Nominal expenditures for Medicaid opioid prescriptions nearly tripled during the study period.
• Morphine derivatives constituted the largest portion of the observed cost increases.
• Opioids accounted for approximately 4% of all Medicaid prescriptions by 2003.
• Substantial variations in per-enrollee opioid spending were observed among states.

Conclusions:

• Opioid utilization and associated costs within the Medicaid program experienced significant growth from 1998 to 2003.
• Morphine derivatives were a primary driver of increased opioid expenditures.
• Considerable geographic disparities in state-level opioid spending exist, the appropriateness of which remains undetermined.